Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Acorda Therapeutics Inc. -- Ignore unavailable to you. Want to Upgrade?

To: kenhott who wrote (57)	10/7/2009 1:39:23 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 120

Ken, First let me thank you for taking the time to share that information about ACORs drug. And double thanks for not detailing what the drug is used for in the real world……no need to scare people out of their ‘socks’. (:>) Truly amazing what some drugs were designed for, but then with the proper ‘dosing’ it can be used by humans. As for the compounding, that is and will be a consideration for patients. However, today the compounding process isn’t something that many local pharma pursue because of having individual ingredients available and then the liability aspect……especially for ACORs ingredient. I think you would agree, the compounding of this drug has to be done with precision---a druggist can’t afford to be off the ‘mark’ with the final compound. Back in my hometown and ages ago when I worked in our little community drug story, people would have been shocked if they knew that was me, a mere high school student, that was behind the counter mixing and blending their doctor’s prescription. But they can be assured; I never worked with anything that has the lethal aspect of what ACOR is working with. The other points that you address, as it relates to issues that MS patients face, the prospect of any improvement in mobility would be a blessing and the willingness to face the ‘black-box’ prospect for a drug will be no problem! I think that ACOR will get approval, but price is pretty well priced into the stock at the current level. But then as you mention, ACOR has a wider pipeline, and a steady revenue flow will certainly give them a better opportunity to develop these other candidates. I personally don't own the stock, however, my daughter owns a few shares. If luck can be applied to this situation considering the reality......she at least has the stock at a lower entry level.